

REMARKS

In the specification, the scopes of variables R^1 ~ R^4 on page 3 are amended with the currently amended claim 1.

To overcome the Examiner's rejection of new matter, Applicant now deletes the proviso "wherein R^2 is not phenyl as R^1 is phenyl" from claim 1.

To overcome the rejection as anticipated by Kang et al., the scope of R^3 and R^4 are redefined by re-presenting "aryl or alkyl of C1-C9" or " R^3 , R^4 and N form a three-to-eight-membered heterocycle", but inserting a proviso " R^3 , R^4 and N form pyrrolidinyl or morpholinyl as R^1 and R^2 are both phenyl". This new proviso is added according to Examples 1~8 and 10 described in the original specification, and therefore the Applicant believes no new matter is concerned.

To overcome the rejection as anticipated by Carreno et al., methyl is deleted from R^5 , i.e., R^5 can be only H.

The above amendments therefore can fully overcome the rejections under 35 U.S.C. 102(b) and 112.

To further clearly define the variables R^1 ~ R^5 , claims 11~17 are added, in which

Claim 11 is added according to compounds (6b4c), (6c4c), (6f4c), (6g4c) and (6g4c), respectively presented in Examples 1, 3, 5~7;

Claim 12 is added according to compounds (2f4c) and (3f4c) presented in Examples 2 and 4;

Claim 13 is added according to compounds (7g4c) and (7g6c) presented in Examples 8 and 10;

Claim 14 is added according to compounds (2g5c) and (4g5c) listed in Table 3;


Claim 15 is added according to compounds (5g2c), (5g3c), (5g4c), (5g5c) and (5g6c) listed in Table 3;

Claim 16 is added according to compounds (6g1c), (6g2c) and (6g6c) listed in Table 3, and compound (6g5c) listed in Table 4;

Claim 17 is added according to compound (6f5c) listed in Table 4.

Applicant believes that the foregoing is a complete response to the Office action, and respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Charles E. Baxley", written over a horizontal line.

Charles E. Baxley

90 John Street-Third Floor
New York, N.Y. 10038-3243
U.S.A.